CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.

• Chlamydia trachomatis is a significant human pathogen with potentially severe disease sequelae in the genital tract, including infertility. A successful vaccine will need to effectively target immunity to the genital mucosa. Intranasal immunisation with cholera toxin (CT) can target immunity to the genital tract, but has the potential to cause neurological side effects. CTA1-DD is a non-toxic potent mucosal adjuvant which combines the enzymatic properties of CT, with a B cell targeting moiety. Here, we demonstrate that intranasal immunisation with CTA1-DD and chlamydial Major Outer Membrane Protein (MOMP) results in the induction of neutralising systemic and mucosal antibodies, and reduces the level of chlamydial shedding following intravaginal challenge with Chlamydia muridarum. Thus, CTA1-DD is an effective adjuvant for vaccine development against Chlamydia trachomatis, and possibly also a range of other genital pathogens.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Mikrobiologi inom det medicinska området (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Microbiology in the medical area (hsv//eng)

Nyckelord

Adjuvants

Immunologic

genetics

therapeutic use

Animals

B-Lymphocytes

drug effects

immunology

metabolism

pathology

Chlamydia Infections

complications

immunology

therapy

Chlamydia muridarum

immunology

pathogenicity

Chlamydia trachomatis

immunology

pathogenicity

Cholera Toxin

genetics

immunology

therapeutic use

Female

Genitalia

immunology

microbiology

pathology

Humans

Immunization

Immunoglobulins

blood

Infertility

etiology

prevention & control

Mice

Mice

Inbred BALB C

Mucous Membrane

immunology

microbiology

pathology

Porins

immunology

Recombinant Fusion Proteins

genetics

immunology

therapeutic use

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)